The research illuminated that people taking bumetanide, which is approved by the US Food and Drug Administration (FDA), had a significantly lower prevalence of Alzheimer’s disease than those not taking the drug.
Subsequently, the team examined the APOE4-specific Alzheimer’s signatures against those of over 1,300 drugs approved by the FDA, of which five demonstrated a gene expression signature that had the potential to neutralise the disease. The most promising of the final candidates was bumetanide, a diuretic employed to remedy fluid retention incurred by medical problems such as kidney, heart, and liver disease.
To further authenticate the potential of the drug signified by the data-driven testing, the team performed examinations of bumetanide on mouse models with Alzheimer’s and induced stem-cell-derived human neurons, finding that the diuretic reduced memory and learning deficits in mice expressing the human APOE4 gene. .
These results were further validated in the human cell-based models, indicating that there should be lower rates of Alzheimer’s in people who were already taking bumetanide.